Long-term prostate cancer survival outcomes including patterns of death in men >=75 years of age treated with low dose rate brachytherapy

Definitive treatment is warranted in appropriately selected elderly men with clinically localized prostate cancer. Patient selection criteria to include the number of comorbidities must be assessed to maximize oncologic outcomes and minimize over-treatment. Men with clinically higher risk prostate cancer and no comorbidities are most likely to benefit from definitive treatment regimens.